British health authorities said on Wednesday they would not recommend Jakavi, a drug produced by Swiss pharmaceutical company Novartis to treat a rare form of blood cancer, deeming it too expensive.
Feb 13, 2013
0
0
(HealthDay)—The anti-cancer drug Gleevec (imatinib) has received new U.S. Food and Drug Administration approval to treat the most common type of pediatric cancer, affecting some 2,900 children each year, the agency said ...
Jan 25, 2013
0
0
Pfizer Inc. says the Food and Drug Administration on Tuesday approved its new drug to treat a rare form of blood and bone marrow cancer.
Sep 4, 2012
0
0
The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial.
May 16, 2012
0
0
In February, the United States came within weeks of running out of preservative-free methotrexate, a generic drug that is an essential component of chemotherapy treatments for the most common childhood cancer, acute lymphoblastic ...
Apr 24, 2012
0
0
Drug manufacturers and the Food and Drug Administration (FDA) scrambled earlier this month to address a sudden shortage of methotrexate, a 60-year-old drug that treats children with severe cases of leukemia and sarcoma. Graham ...
Feb 28, 2012
0
0
Several NGOs protested Thursday at the annual meeting of Novartis against the attempt by the Swiss pharmaceutical group's India company to obtain a patent for its anti-cancer drug Glivec.
Feb 23, 2012
0
0
Several prominent cancer researchers are now joining forces in an advanced new cancer study. The goal is to understand which tumors will be difficult to treat and to find out why certain cancer drugs lose their effect after ...
Aug 18, 2011
0
0
(Medical Xpress) -- Customizing targeted therapies to each tumor's molecular characteristics, instead of a one-size-fits-all approach by tumor type, may be more effective for some types of cancer, according to research conducted ...
Jun 3, 2011
0
0
